Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Payables (2018 - 2025)

Dna X's Payables history spans 8 years, with the latest figure at $9.1 million for Q4 2025.

  • Quarterly results put Payables at $9.1 million for Q4 2025, up 1132.38% from a year ago — trailing twelve months through Dec 2025 was $9.1 million (up 1132.38% YoY), and the annual figure for FY2025 was $9.1 million, up 1132.38%.
  • Payables for Q4 2025 was $9.1 million at Dna X, down from $20.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $23.5 million in Q2 2025 to a low of $738000.0 in Q4 2024.
  • The 5-year median for Payables is $13.0 million (2021), against an average of $14.5 million.
  • The sharpest move saw Payables tumbled 96.28% in 2024, then surged 1132.38% in 2025.
  • Year by year, Payables stood at $9.5 million in 2021, then skyrocketed by 123.01% to $21.1 million in 2022, then dropped by 6.05% to $19.8 million in 2023, then tumbled by 96.28% to $738000.0 in 2024, then surged by 1132.38% to $9.1 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $9.1 million, $20.8 million, and $23.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.